Menu
Recruiting NCT07459699

Effects of Probiotics on the Gut-brain Axis in Children

No phase Interventional Attention Deficit Hyperactivity Disorder (ADHD)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Probiotics, Placebo.
Who it may be relevant to
Registry conditions: Attention Deficit Hyperactivity Disorder (ADHD). Basic parameters: 8 years — 11 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Randomised, Placebo-controlled Pilot Study to Assess the Effects of Probiotics on the Gut-brain Axis in Children With Attention Deficit Hyperactivity Disorder

Overview

The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.

Interventions

  • Dietary supplement Probiotics
    Probiotics in a sachet
  • Dietary supplement Placebo
    Placebo in a sachet

Primary outcome measures

  • Conner's Continuous Performance test-3 (CPT-3) hit reaction time (HRT) block change score [Time frame: 12 weeks]

Eligibility criteria

Inclusion criteria

  • Males and females aged 8 - 11 years
  • With mild ADHD symptoms
  • Patient and parents (legal representatives) able and willing to participate in the research by complying with the protocol procedures

Exclusion criteria

  • Metabolic disorder
  • Severe chronic disease
  • GI disorders found to be inconsistent with the conduct of the study by the investigator
  • Neurological disorder involving central function (e.g., intellectual disability, autism spectrum disorder, epilepsy, narcolepsy)
  • Currently treated with a medication with primary central nervous system activity or major psychiatric condition requiring hospitalization
  • With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredients
  • Having taken prebiotic or probiotic treatment in the month prior to inclusion, or having taken antibiotics for more than one week in the 3 months prior to inclusion,
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
  • Parents (legal representatives) presenting a psychological or linguistic incapability to sign the ICF,
  • Parents (legal representatives) impossible to contact in case of emergency.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

China · 1 center
  • Department of Developmental and Behavioral Pediatrics & Child Health Care Xinhua Hospital — Shanghai

Identifiers

NCT: NCT07459699 · PEB24100

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗